Exicure, Inc. (NASDAQ:XCUR) stock is trading higher on Tuesday. Its session volume was 13.62 million, compared with the average volume of 151.41 thousand, according to data from Benzinga Pro.The company shared results from its Phase 2 trial of burixafor (GPC-100) in combination with propranolol and granulocyte colony-stimulating factor (G-CSF) for the mobilization of hematopoietic progenitor cells (HPCs) in multiple myeloma patients undergoing autologous hematopoietic cell transplantation.The data showed th ...